Jul 6, 2026 07:00AM
May 20, 2026 07:00AM
Mar 25, 2026 07:00AM
Mar 23, 2026 07:00AM
Oct 15, 2025 07:00AM
Oct 15, 2025 07:00AM
Sep 25, 2025 07:00AM Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
Sep 4, 2025 07:00AM
Sep 4, 2025 07:00AM
May 13, 2025 07:00AM
Jul 16, 2024 08:00AM
Mar 27, 2024 12:04PM
Nov 22, 2023 07:00AM
Jun 27, 2023 07:00AM Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Jan 9, 2023 07:00AM
Dec 5, 2022 07:00AM
Sep 19, 2022 07:00AM
Sep 1, 2022 07:00AM
Jul 18, 2022 08:00AM
Feb 23, 2022 07:00AM
Jan 14, 2022 08:15AM Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Dec 2, 2021 07:00AM
Nov 24, 2021 07:00AM
Oct 15, 2021 12:00PM
Oct 13, 2021 07:00AM
Oct 8, 2021 07:00AM
Sep 22, 2021 07:30AM
Sep 20, 2021 07:00AM Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Aug 11, 2021 07:00AM
Aug 9, 2021 07:00AM
Jul 6, 2021 08:30AM
Jun 3, 2021 07:00AM
May 17, 2021 07:00AM
Apr 26, 2021 08:07AM
Apr 26, 2021 08:00AM Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
Apr 8, 2021 07:00AM
Mar 31, 2021 08:00AM
Mar 17, 2021 07:00AM
Feb 19, 2021 08:00AM
Feb 1, 2021 07:30AM
Jan 7, 2021 08:00AM
Dec 30, 2020 08:00AM Algernon Pharmaceuticals Provides Year End Summary of Key Activities
Dec 17, 2020 08:00AM
Dec 15, 2020 08:15AM
Jun 25, 2020 08:00AM
Jun 4, 2020 12:10PM
May 26, 2020 08:49AM
May 25, 2020 08:00AM
May 15, 2020 08:30AM Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
Apr 30, 2020 09:15AM

326,120 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All